APTO News and Press, Aptose Biosciences Inc. From 06/27/23

2023-06-27 05:56:29 ET Clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, Aptose Biosciences ( NASDAQ: APTO ) receives Nasdaq notice that it meets compliance with the Nasdaq’s minimum...

SAN DIEGO and TORONTO, June 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies,...

Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML Patients Favorable safety with monotherapy responses across four dose levels with no DLT in mutationally diverse and difficult to treat R/R AML Populations TP53 MUT CR/CRh = 20% │ RAS MUT C...

2023-06-05 07:45:20 ET Aptose Biosciences ( NASDAQ: APTO ) has effected a reverse stock split on at a ratio of 15-to-1, effective at market open on Tuesday, June 6, 2023. The company had previously announced that the reverse stock split, at a ratio in the range between 10-to-1...

SAN DIEGO and TORONTO, June 05, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, a...

SAN DIEGO and TORONTO, May 31, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancie...

2023-05-25 17:18:09 ET Aptose Biosciences ( NASDAQ: APTO ) ( TSX: APS:CA ) said Thursday it has entered into a $25 million common share purchase agreement and registration rights agreement with an institutional investor. Aptose will sell and issue up to $25 milli...

SAN DIEGO and TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, to...

2023-05-21 10:03:52 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you’re a risk taker on the lookout for stocks with 1000% upside potential, you’d have to venture into speculative territory. It is difficult to find analyst ratings with such...

2023-05-09 10:27:43 ET Aptose Biosciences press release ( NASDAQ: APTO ): Q1 GAAP EPS of -$0.15 misses by $0.03 . Total cash and cash equivalents and investments as of March 31, 2023, were $35.7 million. Based on current operations, the Company expects that cash on han...